Drugs / BMS-986218
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04301414 | Feb 2020 → Mar 2025 | prostate cancer | Columbia University | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04785287 | Mar 2021 → Feb 2026 | adrenal gland cancer, carcinoma of liver and intrahepatic biliary tract, lung carcinoma, metastatic carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03110107 | May 2017 → Apr 2024 | — | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT05169684 | Feb 2022 → Dec 2023 | castration-resistant prostate carcinoma | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS986218 | “anti-CTLA4-NF monoclonal antibody (mAb) (BMS986218), nivolumab” NCT04785287 ↗ |
| Modality | Monoclonal antibody | “Monoclonal Antibody BMS-986218” NCT03110107 ↗ |
| Route | Intravenous | “BMS-986218 20mg IV every 2 weeks x 2 doses starting 3 weeks prior to radical prostatectomy” NCT04301414 ↗ |
| Target | CTLA4 | “an afucosylated anti-CTLA-4 antibody (BMS-986218)” PMID 41759531 ↗ Feb 2026 |